Labcorp Holdings Inc. (LH) Analyst Ratings & Price Targets

Labcorp Holdings Inc.

LH · NYSE

Analyst Consensus

Buy

16 analysts

$368

Current

$395

Low

$360

Average

$395

High

Average target implies -2.22% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 16 analysts, with a stated mean target of $360; the consensus figures do not provide low or high targets. Other supplied snapshots vary: Investing.com reports a $344.81 average and a $293–$385 range, while MarketBeat lists $337.73 and Fintel lists a $306.09 average with a $262.60–$359.10 range. Truist Securities analyst David Macdonald is the most bullish named analyst in the evidence, raising his target to $395 on October 29. The lowest disclosed estimate is $293, but its analyst is not identified. Revisions were positive over the week: Truist raised its target from $365. The spread reflects differing views of valuation and how much Q3 growth and the higher outlook support the share price.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Truist Securities	David Macdonald	Buy Maintained	$395from $365	+7.3%	Oct 29, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

TRUIST SECURITI

UBS

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: LH
Type: Stock
Sector: Health Care
Industry: Medical Specialities
Country: North America
Exchange: NYSE

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world.

Key Issues

Bullish view

Both segments grew in Q3, margins expanded and adjusted EPS growth was double-digit, giving support to the raised full-year outlook.

Bearish view

Quarterly revenue growth was 6.9%; the supplied results establish a strong quarter but do not show whether that pace will persist.

Analyst Consensus

See all

Buy

16 analysts

$368

Current

$395

Low

$360

Average

$395

High

Average target implies -2.22% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Centene CorporationCNC · NYSE$68.58